Nucana PLC (NCNA) — SEC Filings

Nucana PLC (NCNA) — 44 SEC filings. Latest: 6-K (Dec 17, 2025). Includes 38 6-K, 3 SC 13G/A, 2 20-F.

View Nucana PLC on SEC EDGAR

Overview

Nucana PLC (NCNA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 10, 2025: On December 10, 2025, NuCana plc announced the presentation of new clinical data from patients treated with their drug. The press release was filed as a Form 6-K with the SEC.

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 41 neutral. The dominant filing sentiment for Nucana PLC is neutral.

Filing Type Overview

Nucana PLC (NCNA) has filed 38 6-K, 2 20-F, 3 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (44)

Nucana PLC SEC Filing History
DateFormDescriptionRisk
Dec 17, 20256-K6-K Filing
Dec 10, 20256-KNuCana plc Presents New Clinical Datalow
Nov 13, 20256-KNuCana plc Reports Q3 2025 Financial Resultslow
Nov 5, 20256-K6-K Filing
Oct 20, 20256-KNuCana plc Presents New ProTide Technology Datalow
Oct 14, 20256-KNuCana plc Publishes New Data from NuTide:303 Studymedium
Sep 5, 20256-KNuCana plc Confirms Compliance with Credit Facility Covenantslow
Sep 3, 20256-KNuCana to Present Pancreatic Cancer Data at ESMOmedium
Aug 20, 20256-KNuCana plc Files 6-K Report for Q2 2025low
Aug 1, 20256-KNuCana plc Announces ADS Ratio Changelow
Jul 21, 20256-KNuCana plc Cancels Series A Warrantsmedium
Jul 11, 20256-KNuCana plc Plans ADS Ratio Changelow
Jul 9, 20256-KNuCana plc Receives Nasdaq Non-Compliance Noticemedium
Jun 30, 20256-KNuCana plc Secures $50M Sales Agreementmedium
Jun 27, 20256-KNuCana plc Cancels Warrants via Letter Agreementslow
Jun 20, 20256-KNuCana plc Faces Nasdaq Delisting Warningmedium
Jun 18, 20256-KNuCana CEO Hugh S. Griffith Takes Health Leavemedium
Jun 5, 20256-KNuCana plc Releases 2024 UK Annual Reportlow
Jun 2, 20256-KNuCana plc Files Q1 2025 Financial Resultslow
Apr 23, 20256-KNuCana plc Files 6-K Report, Holds General Meetinglow

Risk Profile

Risk Assessment: Of NCNA's 39 recent filings, 0 were flagged as high-risk, 16 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

  • Hugh S. Griffith
  • Donald Munoz
  • Dr. James I. Healy
  • Dr. Maha Katabi

Industry Context

NuCana plc operates within the pharmaceutical preparations industry.

Top Tags

financial-results (6) · pharmaceuticals (6) · filing (5) · sec-filing (5) · annual-report (5) · 6-K (4) · clinical-data (3) · press-release (3) · biotech (3) · clinical-trial-data (3)

Key Numbers

Nucana PLC Key Metrics
MetricValueContext
Reporting PeriodQ2 2025Financials for the second quarter of 2025 are detailed.
Potential Capital Raise$50.0MMaximum amount NuCana plc can raise through the Sales Agreement
Consecutive business days30Below minimum bid price for Nasdaq listing
Fiscal Year End2024-12-31Reporting period for the 20-F
Filing Date2025-03-20Date the 20-F was submitted to the SEC
Days to regain compliance180NuCana plc has 180 days to meet Nasdaq's minimum bid price requirement.
Nominal Value per Share£0.04Nominal value of NuCana plc's ordinary shares

Related Companies

NCA · NCNC

Frequently Asked Questions

What are the latest SEC filings for Nucana PLC (NCNA)?

Nucana PLC has 44 recent SEC filings from Jan 2024 to Dec 2025, including 38 6-K, 3 SC 13G/A, 2 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of NCNA filings?

Across 44 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 41 neutral. The dominant sentiment is neutral.

Where can I find Nucana PLC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Nucana PLC (NCNA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Nucana PLC?

Financial highlights for Nucana PLC are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for NCNA?

The investment thesis for NCNA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Nucana PLC?

Key executives identified across Nucana PLC's filings include Hugh S. Griffith, Donald Munoz, Dr. James I. Healy, Dr. Maha Katabi.

What are the main risk factors for Nucana PLC stock?

Of NCNA's 39 assessed filings, 0 were flagged high-risk, 16 medium-risk, and 23 low-risk.

What are recent predictions and forward guidance from Nucana PLC?

Forward guidance and predictions for Nucana PLC are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.